FDA Adverse Event Injury Summary report: N

XIENCE V EVEROLIMUS ELUTING CORONARY STENT SYSTEM

MDR report key: 1201794 · Received October 15, 2008

Report

Report Number
2024168-2008-00948
Event Type
Injury
Date Received
October 15, 2008
Date of Event
September 12, 2008
Report Date
September 15, 2008
Manufacturer
ABBOTT VASCULAR-CARDIAC THERAPIES
Product Code
NIQ
PMA / PMN Number
P070015
Removal / Correction Number
NA
Adverse Event
Yes
Report Source
Manufacturer report
Reporter Location
NC, US
Reporter Occupation
PHYSICIAN

Narratives

Additional Manufacturer Narrative · 1

RESULTS AND CONCLUSION SUMMATION - PRODUCT PERFORMANCE ENGINEERING REVIEWED THE INCIDENT INFORMATION. STENOSIS, AS LISTED IN THE XIENCE V IFU, IS A KNOWN ADVERSE EVENT ASSOCIATED WITH CORONARY STENTING. THIS EFFECT IS NOT NECESSARILY AN INDICATION OF A PRODUCT QUALITY ISSUE. THE HOSPITALIZATION WAS THE RESULT OF THE RESTENOSIS, ALTHOUGH THE TYPE OF TREATMENT WAS NOT REPORTED. ADDITIONALLY, THERE WAS NO REPORTED DEVICE MALFUNCTION AT THE TIME OF THE PROCEDURE. A CONCLUSIVE ROOT CAUSE CANNOT BE DETERMINED FOR THE REPORTED PATIENT EFFECT AND THE RELATIONSHIP TO THE XIENCE V STENT DELIVERY SYSTEM.

Description of Event or Problem · 1

REPORTING STATUS: SERIOUS INJURY/MEDICAL INTERVENTION. REPORTING RATIONALE: RESTENOSIS REQUIRING MEDICAL INTERVENTION. DEVICE ISSUE: NONE. IT WAS REPORTED VIA TRIAL THAT THE VESSELS TREATED DURING THE INDEX PROCEDURE WERE THE MID LAD AND PROXIMAL RCA. REVASCULARIZATION WAS PERFORMED ON THE MID LAD DUE TO RESTENOSIS DURING WHICH A XIENCE V STENT WAS PLACED FOR TREATMENT. NO ADDITIONAL EVENT OR PATIENT INFORMATION IS AVAILABLE.

Devices

Seq Brand Generic Product Code Manufacturer Model Lot UDI-DI
1 XIENCE V EVEROLIMUS ELUTING CORONARY STENT SYSTEM NIQ ABBOTT VASCULAR-CARDIAC THERAPIES NA 60617P3

Patients

Seq Age Sex Outcome Treatment
1 61 YR Hospitalization| R